Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18630000 | 0.88 | SIGMAR1 (0.50) | SIGMAR1CHRNB2CHRNA4EEDHPGD | |
| SCHEMBL15025467 | 0.88 | SIGMAR1 (0.50) | SIGMAR1CHRNB2CHRNA4EEDHPGD | |
| SCHEMBL20159085 | 0.81 | SIGMAR1 (0.61) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL8348679 | 0.79 | — | — | |
| SCHEMBL9965975 | 0.76 | MAOA (0.59) | SIGMAR1CHRNB2CHRNA4EED | |
| 5,6,7,8-Tetrahydroisoquinoline SCHEMBL28211 | 0.75 | SIGMAR1 (1.00) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL29518090 | 0.75 | — | — | |
| SCHEMBL2388666 | 0.75 | — | — | |
| SCHEMBL14730735 | 0.74 | SIGMAR1 (0.46) | SIGMAR1CHRNB2CHRNA4NAMPT | |
| SCHEMBL9965909 | 0.73 | MAOA (0.55) | SIGMAR1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018086703-A1 | DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |